Search

Home > JACC's Audio Podcasts > Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies | JACC | ACC.25
Podcast: JACC's Audio Podcasts
Episode:

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies | JACC | ACC.25
Category: Science & Medicine
Duration: 00:01:41
Publish Date: 2025-04-01 14:31:46
Description:

This interview with JACC: Associate Editor Neha J. Pagidipati, MD, FACC, and author Kausik Ray, MD, FACC, reviews Dr. Ray’s phase one study on solbinsiran, an siRNA therapy targeting ANGPTL3 to reduce triglycerides and cardiovascular risk. Dr. Ray explains the study's findings, including significant reductions in triglycerides, ApoB, and LDL, with a favorable safety profile. The conversation also touches on the broader landscape of ANGPTL3 inhibitors, the implications of HDL reduction, and the anticipation of phase two results to be presented at ACC 2025.
Total Play: 0

Users also like

100+ Episodes
Podcasts de .. 50+     7
400+ Episodes
CHEST Journa .. 10+     2
1 Episodes
JAMA Cardiol .. 10+     5

Some more Podcasts by American College of Cardiology

500+ Episodes
JACC: Clinic .. 10+     1
1K+ Episodes
JACC Podcast